Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORMP Oramed Pharmaceuticals

Closed 04-20 16:00:00 EDT

3.83

-0.05

-1.29%

盘后3.83

+0.000.00%

19:06 EDT

High3.85	Low3.66	Vol155.36K
Open3.85	D1 Closing3.88	Amplitude4.90%
Mkt Cap154.91M	Tradable Cap114.55M	Total Shares40.45M
T/O585.43K	T/O Rate0.52%	Tradable Shares29.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORMP","market":"US","secType":"STK","nameCN":"Oramed Pharmaceuticals","latestPrice":3.83,"timestamp":1776715200000,"preClose":3.88,"halted":0,"volume":155360,"hourTrading":{"tag":"盘后","latestPrice":3.83,"preClose":3.83,"latestTime":"19:06 EDT","volume":68,"amount":260.44,"timestamp":1776726364464,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012886597938144284,"floatShares":29909699,"shares":40446179,"eps":1.5,"marketStatus":"Closed","change":-0.05,"latestTime":"04-20 16:00:00 EDT","open":3.85,"high":3.85,"low":3.66,"amount":585425.550115,"amplitude":0.048969,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.5,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776758400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.88,"preHourTrading":{"tag":"盘前","latestPrice":3.81,"preClose":3.88,"latestTime":"09:02 EDT","volume":2262,"amount":8598.296304,"timestamp":1776690123670,"change":-0.07,"changeRate":-0.018041,"amplitude":0.010309},"postHourTrading":{"tag":"盘后","latestPrice":3.83,"preClose":3.83,"latestTime":"19:06 EDT","volume":68,"amount":260.44,"timestamp":1776726364464,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.239598,"impliedVol":0.6827,"impliedVolPercentile":0.2869},"requestUrl":"/m/hq/s/ORMP","defaultTab":"news","newsList":[{"id":"2624530347","title":"Oramed completes Oratech sale to Lifeward for shares, warrants, revenue-sharing payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530347","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530347?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:22","pubTimestamp":1774988568,"startTime":"0","endTime":"0","summary":"Oramed completed sale of wholly owned unit Oratech Pharma to Lifeward on March 25, 2026.Transaction includes ongoing revenue-sharing payments set at 4% of net revenue from Lifeward ReWalk Personal Exoskeleton products and related extended warranties.Revenue-sharing term runs up to 10 years, subject to earlier cutoff tied to a maximum payment amount or Lifeward reaching $200 million market capitalization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL7nmf26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4007","BK4082","LFWD","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622914618","title":"Oramed FY2025 profit rises to $64.0 million; revenue climbs to $2.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622914618","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622914618?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:16","pubTimestamp":1774559766,"startTime":"0","endTime":"0","summary":"Oramed published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting revenue of USD 2.0 million.Net income was USD 64.02 million, while net income attributable to stockholders was USD 64.05 million.Research and development expense fell 1% to USD 6.38 million, driven by lower raw materials costs partly offset by higher CRO expenses.General and administrative expense rose 35% to USD 8.72 million, mainly due to higher stock-based compensation and professional fees.Oramed said it ended 2025 with USD 45.95 million in cash and cash equivalents and expects its current cash resources to fund planned activities for at least the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL43TdgB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004431","title":"Lifeward closes strategic partnership with Oramed; access to capital grows to $47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004431","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004431?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:12","pubTimestamp":1774469547,"startTime":"0","endTime":"0","summary":"Lifeward closed a strategic partnership agreement with Oramed.Under the arrangement, Lifeward acquired Oramed’s clinical-stage Protein Oral Delivery  technology.The partnership provides Lifeward access to up to USD 47 million of capital from Oramed and certain investors.Lifeward accessed USD 10 million of that capital at the closing.The company also made changes to its board of directors in connection with the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL3znJfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ORMP","BK4604","BK4007","LFWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004196","title":"Lifeward Successfully Closes on Strategic Partnership With Oramed","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004196","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004196?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:10","pubTimestamp":1774469400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA1B380:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621465081","title":"Oramed Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621465081","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621465081?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296307,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to  show no change in quarterly revenue when it reports ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B2BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619919428","title":"Lifeward to partner with Oramed in deal providing access to up to USD 47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919428","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919428?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:05","pubTimestamp":1773403523,"startTime":"0","endTime":"0","summary":"Lifeward shareholders approved the issuance of ordinary shares tied to a strategic partnership with Oramed. Under the agreement, Lifeward will integrate Oramed’s POD oral delivery technology, and Oramed will obtain a significant equity interest through ordinary shares and prefunded warrants. The investment structure provides Lifeward potential access to up to 47 million of capital through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed is expected to manage and fund the POD platform’s clinical development under a clinical trial management agreement to be entered into at closing. The transaction is expected to close after customary closing conditions are satisfied.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL8ynpzS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","LFWD","BK4604","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619948194","title":"Lifeward Receives Shareholder Approval to Close on Strategic Partnership With Oramed—Creating Diversified Biomedical Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2619948194","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619948194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA95PNHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613290402","title":"Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290402?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:53","pubTimestamp":1771624423,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2026, Oramed Pharmaceuticals entered into a Warrant Agreement with Sc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-restructures-scilex-notes-via-warrant-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-restructures-scilex-notes-via-warrant-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613297527","title":"Scilex Issues 100,000-Share Warrant to Oramed at $20 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297527?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:14","pubTimestamp":1771622096,"startTime":"0","endTime":"0","summary":"Scilex Holding Company entered into a warrant agreement with Oramed Pharmaceuticals under which Scilex will issue Oramed a new warrant to buy 100,000 common shares at an initial exercise price of $20.00 per share. The warrant is immediately exercisable, expires Dec. 13, 2029, and was issued in a private placement exemption, with Scilex agreeing to file a resale registration statement for the underlying shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scilex Holding Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDLbgPqBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SCLX","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612235588","title":"Lifeward Signs $525,000 Secured Promissory Note With Oramed Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235588?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:31","pubTimestamp":1771536703,"startTime":"0","endTime":"0","summary":"Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. on Feb. 12, 2026, for an initial $525,000 that can be increased by up to $975,000 with mutual consent. The note is secured by a lien on Lifeward’s cash, carries 24% annual interest, and matures on the earlier of Aug. 12, 2026 or failure to obtain required shareholder approvals for related transactions. Lifeward also has an earlier $3.0 million secured promissory note outstanding with Oramed Ltd., and any collateral proceeds would be applied ratably to both notes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4kF8wv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["M8216Q309","LFWD","BK4007","BK4604","BK4082","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603642601","title":"Oramed Transfers Oral Drug Platform to Lifeward in Strategic Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642601?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:32","pubTimestamp":1768426325,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has entered into binding agreements with Lifeward Ltd. to transfer its proprietary Protein Oral Drug  delivery technology to Lifeward. As part of the transaction, Oramed will receive a 49.9% beneficial ownership interest in Lifeward, along with warrants. Oramed will continue to manage and fund the upcoming clinical trial for the oral delivery platform. In addition, Oramed will receive 4% of net sales from Lifeward’s ReWalk franchise for up to 10 years. Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, and has generated $26 million in revenue from its FDA-approved ReWalk and AlterG products in the last four quarters. The transaction is expected to advance the oral insulin program and further diversify Lifeward’s biomedical innovation portfolio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8XQX0R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","LFWD","ORMP","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603684341","title":"Lifeward Ltd - Receives up to $47 Mln Investment From Oramed and Another Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684341?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603684305","title":"Lifeward Ltd - Oramed to Buy up to 49.99% Equity in Lifeward","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684305?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603681228","title":"Lifeward Enters Transformative Strategic Investment and Partnership Agreement With Oramed to Create a Diversified Biomedical Innovation Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681228?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603372684","title":"Lifeward Ltd - Buys Oramed's Pod Technology for Biotech Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2603372684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603372684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603681489","title":"BRIEF-Oramed And Lifeward Announce Strategic Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681489","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681489?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:59","pubTimestamp":1768309198,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed And Lifeward Announce Strategic TransactionJan 13 (Reuters) - Lifeward Ltd 2RW.MU:ORAMED AND LIFEWARD ANNOUNCE STRATEGIC TRANSACTIONORAMED PHARMACEUTICALS INC - TO RECEIVE 49.9% OWNERSHIP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603868112","title":"Oramed Invests $9 Million in Lifeward and Transfers Oral Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2603868112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603868112?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309096,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has entered into a strategic transaction with Lifeward Ltd., transferring its proprietary Protein Oral Drug  delivery technology to Lifeward. As part of the agreement, Oramed will obtain a 49.9% beneficial ownership interest in Lifeward and will invest $9 million in a $10 million senior secured convertible note, with the potential to significantly increase its stake through additional milestone-based investments and warrant exercises. Oramed will also fund and manage an anticipated upcoming clinical trial for the technology, marking a significant expansion of its involvement in oral drug delivery innovation and medical robotics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. publi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL8BZHP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ORMP","BK4007","LFWD","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603811496","title":"Oramed Pharmaceuticals Inc - Lifeward to Issue $10 Mln Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2603811496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603811496?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603681409","title":"Oramed Pharmaceuticals Inc - Will Receive 4% on Net Sales of Rewalk Franchise for up to 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681409?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603681146","title":"Oramed Pharmaceuticals Inc - Mark Grant to Lead Combined Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681146?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oramed.com","stockEarnings":[{"period":"1week","weight":0.0992},{"period":"1month","weight":0.0868},{"period":"3month","weight":0.0543},{"period":"6month","weight":0.7399},{"period":"1year","weight":0.8047},{"period":"ytd","weight":0.3614}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.018109},{"month":2,"riseRate":0.538462,"avgChangeRate":-0.018104},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.012814},{"month":4,"riseRate":0.785714,"avgChangeRate":0.026126},{"month":5,"riseRate":0.538462,"avgChangeRate":0.041552},{"month":6,"riseRate":0.384615,"avgChangeRate":0.018782},{"month":7,"riseRate":0.461538,"avgChangeRate":0.04461},{"month":8,"riseRate":0.384615,"avgChangeRate":0.00834},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.048853},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.028699},{"month":11,"riseRate":0.538462,"avgChangeRate":0.137309},{"month":12,"riseRate":0.384615,"avgChangeRate":0.051334}],"exchange":"NASDAQ","name":"Oramed Pharmaceuticals","nameEN":"Oramed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oramed Pharmaceuticals,ORMP,Oramed Pharmaceuticals股票,Oramed Pharmaceuticals股票老虎,Oramed Pharmaceuticals股票老虎国际,Oramed Pharmaceuticals行情,Oramed Pharmaceuticals股票行情,Oramed Pharmaceuticals股价,Oramed Pharmaceuticals股市,Oramed Pharmaceuticals股票价格,Oramed Pharmaceuticals股票交易,Oramed Pharmaceuticals股票购买,Oramed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction